>
产品中心 >
Transfection >
Altogen/Calu-3 Transfection Kit (Lung Carcinoma, HTB-55)/0.5 ml/6401
Description
ProductAvailABIlity:InStock(deliverywithin2-3businessdays,noextrachargefordrop-shipping).
Ordering:ToplaceanorderviacreditcardorPOuseAddtoCartbutton(creatinganaccountisnotrequired).
TransfectionReagentforCalu-3Cells(LungCarcinomaCells,HTB-55)
- Proprietarycationiclipidsformulation
- HightransfectionefficiencyofsmallRNA(siRNA,shRNA,miRNA),mRNA,pDNA
- Effectiveandrobustintracellulardelivery
- KitincludesTransfectionEnhancerreagent
- Producesconsistentresults,lot-to-lot,plate-to-plate,andwell-to-well
- Work inthepresenceofserum
- Aprovenreagentforestablishingstablecelllines
- Optimizedtransfectionprotocolsareadaptedforusewithbothstandard&reversetransfectionmethods
- DownloadinvitroCalu-3 transfectionprotocol:[PDF]
- Download Calu-3CRISPR/Cas9transfectionprotocol:[PDF]
- DownloadPowerPointpresentationforCalu-3cellstransfectionkit:[PPT]
- DevelopedandmanufacturedbyAltogenBiosystems
TransfectionEfficiency:
Reagentexhibitsatleast90%transfectionefficiencyofsiRNAdelivery.TransfectionefficiencywasdeterminedbyqRT-PCR.
TransfectionProtocolandMSDS:
DownloadAltogenBiosystemsTransfectionProtocol:[PDF]
DownloadMSDS:[PDF]
Calu-3 CellLine:
Despitethehighlypreventablenatureoflungcancer,itremainsthesecondmostcommoncancerintheworldandhashighermortalityratesthancolon,breast,andprostatecancerscombined.LungcanceriscontinuouslylistedamongtheleADIngcausesofdeatharoundtheglobe,andfurtherresearchisneededtofindadefinitecure.Preclinicalresearchisanessentialelementforunderstandingtumorgrowthdynamicsanditsinteractionwiththeimmunesystem.Originallyderivedfromthelungtissueofa25-year-oldCaucasianmalewithadenocarcinoma,thetumOrigenicCalu-3celllinehasanepithelialcellmorphologyandisasuitablehostforstudiesrelatedtolungcanceraswellasforotherbiomedicalapplications.ThispatientwastreatedwithCytoxan,Bleomycin,andAdriamycinbeforeremovalofcells.AltogenBiosystemsprovidesefficientlipid-basedtransfectionreagentkitsfortheCalu-3lungcancercellline.
Data:
Figure1.siRNAstargetingLaminA/CmRNAornon-silencingcontrolsiRNAweretransfectedintoCalu-3cellsfollowingtherecommendedprotocol.At48hourspost-transfectionthecellswereanalyzedbyqRT-PCRforLaminA/Cgeneexpressionlevels.18SrRNAlevelswereusedtonormalizetheLaminA/Cdata.Valuesarenormalizedtountreatedsample.Dataaremeans±SD(n=4).
Figure2.ProteinexpressionofLaminA/CinCalu-3cells.DNAplasmidexpressingLaminA/CorsiRNAtargetingLaminA/CweretransfectedintoCalu-3cellsfollowingAltogenBiosystemstransfectionprotocol.At72hourspost-transfectionthecellswereanalyzedbyWesternBlotforproteinexpressionlevels(normalizedbytotalprotein,10µgoftotalproteinloadedpereachwell).Untreatedcellsusedasanegativecontrol.
Calu-3TransfectionKit
AltogenBiosystems:
AltogenBiosystemsprovidespre-optimizedtransfectionkitsandelectroporationproductsforlifescienceresearch.Transfectionproductsaredevelopedforindividualcancercelllineandtransfectionprotocolsareoptimizedtoenablehightransfection efficiencyofbiomolecules.AltogenBiosystemsdevelopedinvivodeliveryproductsforsmallanimalresearch,mouseandrattargetedtissuedelivery:livertargeted,pancreastargeted,kidneytargeted,PEG-Liposome-,Nanoparticle-,Lipid-,andPolymer-basedinvivotransfectionkits.Advancedformulationofreagentsandoptimizedtransfectionprotocolsprovideefficientintracellulardeliveryofbiomolecules.Readmore abouttransfectiontechnologyatAltogen’sTransfectionResource.
AltogenLabsResearchServices:
AltogenLabsprovidesGLP-compliantcontractresearchstudiesforpre-clinicalresearch,INDapplications,anddrugdevelopment.BIOLOGyCROservices include:Xenograftmodels(30+),developmentofstablecelllines,ELISAassaydevelopment,cell-basedandtissuetargetedRNAistudies,safetypharm/toxassays,andotherstudies(visitAltogenLabs.com).
VolumeOptions:
- 0.5ml(Catalog#6401)
- 1.5ml(Catalog#6402)
- 1.5mlCRISPR(Catalog#2124)
- 8.0ml(Catalog#6403)
